Type 1 Diabetes – ACT18368
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study.
The goal of this Phase 2a study is to assess safety and efficacy of SAR442970 in comparison to placebo to preserve β-cell function in participants with recently diagnosed type 1 diabetes (T1D) on insulin therapy.
Inclusion Criteria:
- Participant must be 18 to 35 y.o. inclusive, at the time of signing the informed consent in order to be enrolled in Part A. Participant must be 12 to 21 y.o. inclusive, at the time of signing the informed consent in order to be enrolled in Part B.
- Participants who meet the criteria of T1D according to American Diabetes Association (ADA 2024).
- Initiated exogenous insulin replacement therapy not longer than 90 days prior to Screening visit at which random C-peptide will be assessed.
Other criteria may apply.
Complete the form and our team will reach out soon to help determine your eligibility.
